Insulin Aspart (rDNA) USP

Composition: Mypart: Each ml solution contains Insulin Aspart (rDNA) USP 100IU (Eqv. to 3.5mg).

Indications: Insulin Aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.


Subcutaneous Injection:Insulin Aspart should be administered by subcutaneous

injection in the abdominal region, buttocks, thigh, or upper arm. Because Insulin Aspart has a more rapid onset and a shorter duration of activity than human

regular insulin, it should be injected immediately (within 5-10 minutes) before a meal. Blood glucose monitoring is essential in all patients with diabetes. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosage.Injection sites should be rotated within the same region from one injection to the next to reduce the risk of lipodys trophy.

Intravenous Use:Insulin Aspart can be administered intravenously under

medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous

use, Insulin Aspart should be used at concentrations from 0.05 U/ml to 1.0 U/ml Insulin Aspart in infusion systems using polypropylene infusion bags. Insulin Aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride. Inspect Insulin Aspart for particulate matter and discoloration prior to parenteral

administration. Or, as directed by the registered physician.

Use in Pregnancy and Lactation: Pregnancy: Pregnancy category B. Careful monitoring of glucose control is essential in pregnant patients because insulin

requirements change during different stages of pregnany. Therefore, female patients should be advised to tell their physician if they intend to become or if they

become pregnant while taking Insulin Aspart.

Lactation: It is unknown whether Insulin Aspart is excreted in human milk. Use of Insulin Aspart is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses.

Packing: Mypart: Each box contains 1x3ml vial.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.